AU2006331790A1 - Topical mecamylamine formulations for ocular administration and uses therof - Google Patents

Topical mecamylamine formulations for ocular administration and uses therof Download PDF

Info

Publication number
AU2006331790A1
AU2006331790A1 AU2006331790A AU2006331790A AU2006331790A1 AU 2006331790 A1 AU2006331790 A1 AU 2006331790A1 AU 2006331790 A AU2006331790 A AU 2006331790A AU 2006331790 A AU2006331790 A AU 2006331790A AU 2006331790 A1 AU2006331790 A1 AU 2006331790A1
Authority
AU
Australia
Prior art keywords
mecamylamine
formulation
eye
concentration
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006331790A
Other languages
English (en)
Inventor
John P. Cooke
Muralitharan Kengatharan
Harun Takruri
Xiaoming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CoMentis Inc
Original Assignee
CoMentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoMentis Inc filed Critical CoMentis Inc
Publication of AU2006331790A1 publication Critical patent/AU2006331790A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006331790A 2005-12-19 2006-12-18 Topical mecamylamine formulations for ocular administration and uses therof Abandoned AU2006331790A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75180805P 2005-12-19 2005-12-19
US60/751,808 2005-12-19
US83860506P 2006-08-17 2006-08-17
US60/838,605 2006-08-17
US85958206P 2006-11-17 2006-11-17
US60/859,582 2006-11-17
PCT/US2006/048487 WO2007075720A2 (en) 2005-12-19 2006-12-18 Topical mecamylamine formulations for ocular administration and uses thereof

Publications (1)

Publication Number Publication Date
AU2006331790A1 true AU2006331790A1 (en) 2007-07-05

Family

ID=38218545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006331790A Abandoned AU2006331790A1 (en) 2005-12-19 2006-12-18 Topical mecamylamine formulations for ocular administration and uses therof

Country Status (9)

Country Link
US (1) US20070167526A1 (enExample)
EP (1) EP1978926A2 (enExample)
JP (1) JP2009519962A (enExample)
KR (1) KR20080081175A (enExample)
AU (1) AU2006331790A1 (enExample)
BR (1) BRPI0620080A2 (enExample)
CA (1) CA2633655A1 (enExample)
IL (1) IL192206A0 (enExample)
WO (1) WO2007075720A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
WO2012118833A2 (en) * 2011-02-28 2012-09-07 The Trustees Of Columbia University In The City Of New York Identificationof c3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed animals
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA3002384C (en) * 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6490124B2 (ja) * 2017-03-07 2019-03-27 ファナック株式会社 レーザ加工装置および機械学習装置
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2831027A (en) * 1955-06-06 1958-04-15 Merck & Co Inc Isocamphane compounds and processes for preparing the same
KR830002802B1 (ko) * 1978-12-04 1983-12-16 제임스 에프 · 너우톤 박테리아 발효에 의한 다당류 s-60의 제조방법
US4326053A (en) * 1978-12-04 1982-04-20 Merck & Co., Inc. Polysaccharide S-60 and bacterial fermentation process for its preparation
US5686448A (en) * 1983-01-10 1997-11-11 Baltech, Inc. Treatment of virus infections with ganglionic blocking agents
US4503038A (en) * 1983-02-25 1985-03-05 The Regents Of The University Of California Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
DK1083889T3 (da) * 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DK1634498T3 (da) * 1998-12-16 2008-12-15 Univ South Florida Exo-S-mecamylamine formulation
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
BR0012787A (pt) * 1999-07-28 2002-07-30 Univ Leland Stanford Junior Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora
JP2003505507A (ja) * 1999-07-28 2003-02-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 治療的血管新生および脈管形成におけるニコチン
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
WO2001052832A1 (en) * 2000-01-18 2001-07-26 Valley Forge Pharmaceuticals, Inc. Ocular growth and nicotinic antagonists
US20030096831A1 (en) * 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
JP3683235B2 (ja) * 2002-07-03 2005-08-17 松下電器産業株式会社 密閉型圧縮機
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US8512717B2 (en) * 2003-08-07 2013-08-20 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050075702A1 (en) * 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
BRPI0620080A2 (pt) 2011-11-01
KR20080081175A (ko) 2008-09-08
CA2633655A1 (en) 2007-07-05
IL192206A0 (en) 2009-02-11
US20070167526A1 (en) 2007-07-19
WO2007075720A8 (en) 2008-07-31
EP1978926A2 (en) 2008-10-15
WO2007075720A2 (en) 2007-07-05
WO2007075720A3 (en) 2008-01-31
JP2009519962A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
US11534396B2 (en) Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
US11786510B2 (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
US20230089914A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
US11738007B2 (en) Treatment of glaucoma using endothelin receptor antagonists
US20070167526A1 (en) Topical mecamylamine formulations for ocular administration and uses thereof
JP7571037B2 (ja) 眼表面疼痛を治療する方法
US20240342202A1 (en) Methods of Treating Retinal Vasculopathies
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
MX2008008016A (en) Topical mecamylamine formulations for ocular administration and uses therof
US20250025452A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
Konstas et al. Preservative-Free Gel-Formulated Glaucoma Therapies: Learning from the Past, Looking to the Future
CN101374499A (zh) 用于眼部施用的局部用美加明制剂及其用途
WO2025128712A1 (en) Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period